PMID- 35590283 OWN - NLM STAT- MEDLINE DCOM- 20220523 LR - 20220716 IS - 1471-2369 (Electronic) IS - 1471-2369 (Linking) VI - 23 IP - 1 DP - 2022 May 19 TI - Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study. PG - 191 LID - 10.1186/s12882-022-02818-3 [doi] LID - 191 AB - AIM: The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities. The time to onset, mortality, and hospitalization rates of PPI-related SIADH were also investigated. RESULTS: The study identified a total of 273 reports of PPI-associated SIADH, which appeared to influence more elderly than middle-aged patients (71.1% vs. 12.5%). Women were more affected than men (48.7% vs. 41.8%). Rabeprazole had a stronger SIADH association than other PPIs based on the highest reporting odds ratio (reporting odds ratio = 13.3, 95% confidence interval (CI) = 7.2, 24.9), proportional reporting ratio (proportional reporting ratio = 13.3, chi(2) = 113.7), and empirical Bayes geometric mean (empirical Bayes geometric mean = 13.3, 95% CI = 7.9). The median time to SIADH onset was 22 (interquartile range 6-692) days after PPI administration. PPI-associated SIADH generally led to a 2.95% fatality rate and a 79.7% hospitalization rate. The highest hospitalization death rate occurred in esomeprazole (91.2%). CONCLUSION: According to our findings, more attention should be paid to SIADH within the first several months after the administration of PPIs. For women older than 65 years, dexlansoprazole may reduce the incidence of PPI-associated SIADH. Nonetheless, larger epidemiological studies are suggested to verify this conclusion. CI - (c) 2022. The Author(s). FAU - Wang, Mengmeng AU - Wang M AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zhang, Lingjian AU - Zhang L AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. AD - Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, 611130, PR China. FAU - Jia, Min AU - Jia M AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Wang, Junyan AU - Wang J AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Shen, Zhiwen AU - Shen Z AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Wang, Shuyue AU - Wang S AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zhang, Xinghui AU - Zhang X AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Xu, Jing AU - Xu J AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zheng, Zheng AU - Zheng Z AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Lv, Xuanrui AU - Lv X AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zong, Xiaoyu AU - Zong X AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Li, Hui AU - Li H AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zhou, Jin AU - Zhou J AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Meng, Tong AU - Meng T AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Chen, Mingzhu AU - Chen M AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. FAU - Zhao, Bin AU - Zhao B AD - Department of Pharmacy, Peking Union Medical College Hospital, Beijing, 100730, PR China. FAU - Gong, Jian AU - Gong J AD - Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, P.O.Box 88, No.103 Wenhua Road, Shenyang, 110016, P.R. China. gongjian_1979@163.com. LA - eng PT - Journal Article DEP - 20220519 PL - England TA - BMC Nephrol JT - BMC nephrology JID - 100967793 RN - 0 (Proton Pump Inhibitors) RN - 11000-17-2 (Vasopressins) SB - IM MH - Adverse Drug Reaction Reporting Systems MH - Aged MH - Bayes Theorem MH - Female MH - Humans MH - *Inappropriate ADH Syndrome/chemically induced/epidemiology MH - Male MH - Middle Aged MH - Pharmacovigilance MH - Proton Pump Inhibitors/adverse effects MH - Vasopressins PMC - PMC9121555 OTO - NOTNLM OT - Adverse event reporting system OT - Clinical drug evaluation OT - Pharmacoepidemiology OT - Proton pump inhibitors OT - Syndrome of inappropriate antidiuretic hormone secretion COIS- The authors declare that they have no competing interests. EDAT- 2022/05/20 06:00 MHDA- 2022/05/24 06:00 PMCR- 2022/05/19 CRDT- 2022/05/19 23:45 PHST- 2021/03/11 00:00 [received] PHST- 2022/05/05 00:00 [accepted] PHST- 2022/05/19 23:45 [entrez] PHST- 2022/05/20 06:00 [pubmed] PHST- 2022/05/24 06:00 [medline] PHST- 2022/05/19 00:00 [pmc-release] AID - 10.1186/s12882-022-02818-3 [pii] AID - 2818 [pii] AID - 10.1186/s12882-022-02818-3 [doi] PST - epublish SO - BMC Nephrol. 2022 May 19;23(1):191. doi: 10.1186/s12882-022-02818-3.